ES2539105T3 - Células mesenquimatosas y osteoblastos procedentes de células madre embrionarias humanas - Google Patents
Células mesenquimatosas y osteoblastos procedentes de células madre embrionarias humanas Download PDFInfo
- Publication number
- ES2539105T3 ES2539105T3 ES02756367.5T ES02756367T ES2539105T3 ES 2539105 T3 ES2539105 T3 ES 2539105T3 ES 02756367 T ES02756367 T ES 02756367T ES 2539105 T3 ES2539105 T3 ES 2539105T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- embryonic stem
- human embryonic
- mesenchymal
- osteoblast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000000963 osteoblast Anatomy 0.000 title abstract description 7
- 210000001671 embryonic stem cell Anatomy 0.000 title abstract 2
- 239000001963 growth medium Substances 0.000 abstract description 8
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 abstract description 2
- 229960005070 ascorbic acid Drugs 0.000 abstract description 2
- 239000011668 ascorbic acid Substances 0.000 abstract description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract description 2
- 229960003957 dexamethasone Drugs 0.000 abstract description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 34
- 102100021579 Enhancer of filamentation 1 Human genes 0.000 description 8
- 101800000791 Hemagglutinin-esterase-fusion glycoprotein chain 1 Proteins 0.000 description 8
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 8
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 108010017842 Telomerase Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 3
- 102000004067 Osteocalcin Human genes 0.000 description 3
- 108090000573 Osteocalcin Proteins 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/04—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from germ cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Un medio de cultivo para obtener osteoprogenitores y/u osteoblastos a partir de células madre embrionarias humanas (hES) o su progenie, que comprende BMP4, dexametasona y ácido ascórbico o uno de sus análogos.
Description
5
10
15
20
25
30
35
40
45
50
55
E02756367
10-06-2015
Se transdujo una subpoblación para expresar la transcriptasa inversa de la telomerasa humana (hTERT). Esto se logró infectando con un constructo retrovírico pBABE puro hTERT, que contenía la secuencia codificante de hTERT controlada por MoLV LTR y el gen de resistencia a la puromicina controlado por el promotor temprano SV40. Se reemplazó el medio de crecimiento con una mezcla que contenía 5 mL de patrón retrovírico (1 x 106 pfu/mL) y 4 µg/mL de polybrene y se incubó a 37 ºC. Después de 8 h, se añadieron 5 mL adicionales de la mezcla retrovirus/polybrene y las células se incubaron a 37 ºC. Al día siguiente, la mezcla retrovirus/polybrene se retiró y se reemplazó con medio de crecimiento fresco. Al día siguiente se reemplazó el medio con medio de crecimiento suplementado con 0.5 microgramos/mL de puromicina. Se dividieron las células una vez a la semana con una relación de 1:4 durante 8 semanas en medio que contenía puromicina y se probaron para determinar su actividad telomerasa.
La Figura 2 (Cuadro A) muestra la morfología de la línea celular telomerizada HEF1. El cuadro B (debajo) muestra la actividad telomerasa, según se ha medido con el ensayo TRAP. Las células transducidas con el casete de expresión de hTERT mostraron una actividad telomerasa positiva 20 o 65 días después de la transducción. La línea celular sin transducir, o las células transducidas con el vector de control no mostraron actividad telomerasa. Tanto las células HEF1 transducidas con hTERT como las células transducidas con el vector de control, duplicaron su cantidad aproximadamente una vez cada 2 días, hasta el día 38, cuando las células de control cesaron de dividirse. Las células transfectadas con hTERT continuaron proliferando más allá de los 60 días (30 duplicaciones) con una velocidad de crecimiento constante.
El medio de crecimiento de las células ES se acondicionó como en el Ejemplo 8, utilizando células HEF1 irradiadas con 6000 rad, y se sembraron con una densidad de ~4.1 a 5.5 x 104 células cm-2. Se probó el medio para determinar su capacidad de favorecer el crecimiento de la línea celular hES H9 cultivada en un sustrato Matrigel®. Las células hES se mantuvieron utilizando el medio acondicionado para HEF1 durante más de 4 pases, mostraron morfología de células ES indiferenciadas y mantuvieron la expresión de hTERT y Oct-4.
Ejemplo de referencia 3: Diferenciación adicional en células similares a osteoblastos
Las células ES humanas (línea celular H1, pase 30) se mantuvieron en condiciones exentas de alimentadoras, como se ha descrito anteriormente. Para su uso en este experimento, las células hES se sembraron con una densidad de ~1 × 105 cm-2 en Matrigel® en medio acondicionado para mEF. Las células HEF1 telomerizadas se colocaron en placas con una densidad de 3.1 × 103 cm-2 en DMEM con un 10% de FBS, un 1% de aminoácidos no esenciales y Lglutamina 2 mM. Las células madre mesenquimatosas humanas (hMSC) normales se obtuvieron de BioWhittaker Inc., MD (una filial de Cambrex Co.). Se mantuvieron en medio de crecimiento para MSC (BioWhittaker Part n.º PT3001) de acuerdo con las indicaciones del proveedor. La línea celular de fibroblastos BJ5ta (Bodnar et al., Science 279:349, 1998) se mantuvo en un medio estándar constituido por un 10% de FBS en 1:3 M199/DMEM.
Dos días después del último pase, cada medio de cultivo se reemplazó por medio de inducción de osteoblastos (OIM) para inducir la diferenciación. La base del OIM fue el medio de crecimiento para MSC (ClonTech n.º de cat. PT-3238) (patente de los EE. UU. 5 486 359) suplementado con dexametasona 0.1 µM, ácido 2-fosfato ascórbico 5 µM, β-glicerofosfato 10 mM y 100 ng/mL de BMP-4. Las células se alimentaron con OIM fresco cada 2-3 días.
Después de 11 días en OIM, todas las células mostraron cambios en la morfología celular. Las células HEF1, hMSC y células BJ cambiaron de una forma en husillo a una forma cuboidal y algunas células se volvieron planas. Las células hES mostraron una morfología heterogénea que parecía ser una población diferenciada mixta.
Las células se fijaron con paraformaldehído al 2% en PBS durante 20 min, se lavaron con PBS y se analizaron para determinar los marcadores de osteoblastos. Se detectó la fosfatasa alcalina (AP) con sustrato Vector (Vector Laboratories, Inc., Burlingame, CA). La expresión de AP estuvo claramente ubicada en agrupaciones de células, células H1 diferenciadas así como también células HEF1, BJ y hMSC.
Las proteínas matriciales producidas por los osteoblastos, colágeno-1 y osteocalcina se detectaron mediante inmunotinción. Se permeabilizaron los cultivos mediante tratamiento con EtOH al 100% durante 2 min. Después de los lavados en PBS, se incubaron los cultivos con un 5% de suero de cabra normal en PBS durante 2 h y a continuación con anticuerpo de conejo primario contra el colágeno-1 (1:10, Monosan n.º de cat. P5041) u osteocalcina (1:50, Biomedical Technologies Inc. n.º de cat. 13T593). La tinción se reveló con el anticuerpo secundario anti-inmunoglobulina de conejo producido en cabra marcado con FITC (1:100, Southern Biotechnology Associates inc. n.º de cat. 4050-02).
La Figura 3 muestra los resultados. Los cuadros A y B muestran los resultados inmunocitoquímicos de los marcadores osteocalcina y colágeno-1. El cuadro C muestra la tinción de la actividad fosfatasa alcalina. Estos rasgos son característicos de las células del linaje de osteoblastos.
Estos datos son coherentes con la hipótesis de que tanto las células hES como las células HEF1 tienen la capacidad de generar osteoblastos cuando se someten a un protocolo de diferenciación apropiado in vitro.
15
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30373201P | 2001-07-06 | 2001-07-06 | |
| US303732P | 2001-07-06 | ||
| PCT/US2002/020998 WO2003004605A2 (en) | 2001-07-06 | 2002-07-03 | Mesenchymal cells and osteoblasts from human embryonic stem cell |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2539105T3 true ES2539105T3 (es) | 2015-06-26 |
Family
ID=23173436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02756367.5T Expired - Lifetime ES2539105T3 (es) | 2001-07-06 | 2002-07-03 | Células mesenquimatosas y osteoblastos procedentes de células madre embrionarias humanas |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20030021771A1 (es) |
| EP (1) | EP1412481B1 (es) |
| JP (1) | JP2004535808A (es) |
| CN (2) | CN1636054A (es) |
| AU (1) | AU2002322379B2 (es) |
| CA (1) | CA2453068C (es) |
| ES (1) | ES2539105T3 (es) |
| GB (1) | GB2392674B (es) |
| HK (1) | HK1141552A1 (es) |
| IL (2) | IL159578A0 (es) |
| WO (1) | WO2003004605A2 (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| CA2435826A1 (en) * | 2001-01-24 | 2002-08-01 | The Government Of The United States Of America | Differentiation of stem cells to pancreatic endocrine cells |
| US20030211605A1 (en) * | 2001-05-01 | 2003-11-13 | Lee Sang-Hun | Derivation of midbrain dopaminergic neurons from embryonic stem cells |
| GB0222846D0 (en) | 2002-10-03 | 2002-11-06 | Choo Yen | Cell culture |
| ES2571355T3 (es) | 2002-12-16 | 2016-05-24 | Technion Res & Dev Foundation | Sistema de cultivo sin células alimentadoras ni xenocontaminantes para células madre embrionarias humanas |
| US20030224411A1 (en) * | 2003-03-13 | 2003-12-04 | Stanton Lawrence W. | Genes that are up- or down-regulated during differentiation of human embryonic stem cells |
| JP2005304443A (ja) * | 2004-04-26 | 2005-11-04 | Institute Of Physical & Chemical Research | 前駆間葉系幹細胞 |
| AU2005243158B2 (en) * | 2004-05-07 | 2010-03-25 | Wisconsin Alumni Research Foundation | Method of forming mesenchymal stem cells from embryonic stem cells |
| JP2007536935A (ja) * | 2004-05-14 | 2007-12-20 | ベクトン・ディキンソン・アンド・カンパニー | 間葉幹細胞の無血清増殖のための細胞培養環境 |
| EP2267116B1 (en) | 2004-07-13 | 2017-05-31 | Asterias Biotherapeutics, Inc. | Growth medium for primate embryonic stem cells |
| JP5462483B2 (ja) * | 2005-04-12 | 2014-04-02 | メゾブラスト，インコーポレーテッド | 組織非特異的アルカリホスファターゼによる成体多能性細胞の単離 |
| JP5560391B2 (ja) | 2005-06-22 | 2014-07-23 | アステリアス バイオセラピューティクス インコーポレイテッド | ヒト胚性幹細胞の懸濁培養法 |
| WO2007013430A1 (ja) * | 2005-07-29 | 2007-02-01 | Matsumoto Dental University | 歯の再生方法 |
| AU2006286149B2 (en) | 2005-08-29 | 2012-09-13 | Technion Research And Development Foundation Ltd. | Media for culturing stem cells |
| KR20080056182A (ko) * | 2005-09-02 | 2008-06-20 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 간엽 줄기 세포의 유도 방법 |
| GB0526664D0 (en) * | 2005-11-30 | 2006-02-08 | Plasticell Ltd | Method |
| US8343762B2 (en) * | 2006-01-11 | 2013-01-01 | Technion Research & Development Foundation Ltd. | Human embryonic stem cell-derived connective tissue progenitors for tissue engineering |
| CA2640794C (en) | 2006-02-16 | 2015-04-14 | Universite Libre De Bruxelles | A method for osteogenic differentiation of bone marrow stem cells (bmsc) and uses thereof |
| WO2007122233A1 (en) * | 2006-04-25 | 2007-11-01 | Vrije Universiteit Brussel | Preparation of mesenchymal progenitor cells, particularly osteogenic progenitor cells |
| ES2874223T3 (es) | 2006-08-02 | 2021-11-04 | Technion Res & Dev Foundation | Métodos de expansión de células madre embrionarias en un cultivo en suspensión |
| KR20090043559A (ko) * | 2006-08-15 | 2009-05-06 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 중간엽 줄기세포 조절배지 |
| US20080132424A1 (en) * | 2006-10-02 | 2008-06-05 | Raimund Strehl | Novel toxicity assay based on human blastocyst-derived stem cells and progenitor cells |
| KR100937456B1 (ko) * | 2007-08-01 | 2010-01-19 | 한국생명공학연구원 | 인간배아줄기세포를 조골세포 직계열로 분화시키는 방법 |
| SG174426A1 (en) * | 2009-03-20 | 2011-10-28 | Angioblast Systems Inc | Production of reprogrammed pluripotent cells |
| KR101812817B1 (ko) | 2009-06-25 | 2017-12-27 | 제론 코포레이션 | 무관계 표현형이 고갈된 분화된 다능성 줄기 세포 자손 |
| KR101135636B1 (ko) * | 2009-10-27 | 2012-04-17 | 서울대학교산학협력단 | 인간 만능줄기세포로부터 중배엽 줄기세포를 생산하는 방법 및 이에 의해 생성된 중배엽 줄기세포 |
| JP6276918B2 (ja) | 2009-11-12 | 2018-02-07 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 多能性幹細胞を未分化状態で培養する培地、細胞培養および方法 |
| WO2011124741A1 (es) * | 2010-04-08 | 2011-10-13 | Fundación Progreso Y Salud | Uso de un medio de cultivo condicionado por células madre mesenquimales para la diferenciación de células madre pluripotentes humanas |
| AU2011236653B2 (en) | 2010-04-08 | 2016-10-27 | The University Court Of The University Of Edinburgh | Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof |
| JP2013530699A (ja) | 2010-06-15 | 2013-08-01 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 生物学的応答の調査のための既製の幹細胞モデルの概要 |
| EP2691512B1 (en) | 2011-03-29 | 2019-05-01 | Asterias Biotherapeutics, Inc. | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells |
| CN103083653B (zh) * | 2011-10-28 | 2015-07-22 | 辽宁成大动物药业有限公司 | 一种采用微载体高密度细胞培养技术生产猪瘟活疫苗的方法 |
| CN103777009B (zh) * | 2012-10-18 | 2016-03-02 | 辽宁成大动物药业有限公司 | 一种使用辣根过氧化物酶标抗体检测猪瘟弱毒病毒滴度的方法 |
| ES2730325T3 (es) | 2014-04-24 | 2019-11-11 | Univ Texas | Aplicación de citoblastos pluripotentes inducidos para generar productos de terapia celular adoptiva |
| US11285177B2 (en) | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
| CN108570448B (zh) * | 2018-01-26 | 2019-04-02 | 皓昇莱生物制药有限公司 | 一种高效的hPSCs向MSCs分化的方法 |
| EP3960848A4 (en) * | 2019-04-23 | 2023-07-26 | Cellatoz Therapeutics, Inc. | METHOD FOR REGULATING SELECTIVE DIFFERENTIATION OF MUSCULOSKELETAL STEM CELLS |
| CN113462642A (zh) * | 2021-08-12 | 2021-10-01 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 间充质干细胞的快速诱导分化方法、试剂盒及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5654186A (en) * | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
| US5681701A (en) * | 1993-07-12 | 1997-10-28 | Mayo Foundation For Medical Education And Research | Immortalized human fetal osteoblastic cells |
| US5691175A (en) * | 1993-07-12 | 1997-11-25 | Mayo Foundation For Medical Education And Research | Immortalized human fetal osteoblastic cells |
| US5972703A (en) * | 1994-08-12 | 1999-10-26 | The Regents Of The University Of Michigan | Bone precursor cells: compositions and methods |
| US5843780A (en) * | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| ATE288480T1 (de) * | 1995-11-16 | 2005-02-15 | Univ Case Western Reserve | Chondrogene in vitro induktion von menschlichen mensenchymalen stammzellen |
| US6482231B1 (en) * | 1995-11-20 | 2002-11-19 | Giovanni Abatangelo | Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative |
| US6200606B1 (en) * | 1996-01-16 | 2001-03-13 | Depuy Orthopaedics, Inc. | Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration |
| US6090622A (en) * | 1997-03-31 | 2000-07-18 | The Johns Hopkins School Of Medicine | Human embryonic pluripotent germ cells |
| US6077987A (en) * | 1997-09-04 | 2000-06-20 | North Shore-Long Island Jewish Research Institute | Genetic engineering of cells to enhance healing and tissue regeneration |
| AU1197699A (en) * | 1997-10-23 | 1999-05-10 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
| US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| EP1129176A4 (en) * | 1998-11-09 | 2002-10-30 | Es Cell Int Pte Ltd | EMBRYONIC STEM CELLS |
| ATE408667T1 (de) * | 1999-07-20 | 2008-10-15 | Univ Southern California | Identifizierung pluripotenter prämesenchymaler, prähämotopoietischer vorläuferzellen |
| EP1226239A4 (en) * | 1999-10-15 | 2003-02-12 | Advanced Cell Tech Inc | Process for the preparation of differentiated progenitor cells and embryonic stem cells with line defects |
| AU1618201A (en) * | 1999-11-19 | 2001-05-30 | Children's Medical Center Corporation | Methods for inducing chondrogenesis and producing de novo cartilage in vitro |
| GB0003930D0 (en) * | 2000-02-18 | 2000-04-12 | King S College London | Cell |
| US20040224403A1 (en) * | 2001-12-07 | 2004-11-11 | Robarts Research Institute | Reconstituting hematopoietic cell function using human embryonic stem cells |
-
2002
- 2002-07-03 US US10/189,154 patent/US20030021771A1/en not_active Abandoned
- 2002-07-03 JP JP2003510764A patent/JP2004535808A/ja active Pending
- 2002-07-03 CA CA2453068A patent/CA2453068C/en not_active Expired - Lifetime
- 2002-07-03 IL IL15957802A patent/IL159578A0/xx unknown
- 2002-07-03 AU AU2002322379A patent/AU2002322379B2/en not_active Ceased
- 2002-07-03 GB GB0400481A patent/GB2392674B/en not_active Expired - Fee Related
- 2002-07-03 EP EP02756367.5A patent/EP1412481B1/en not_active Expired - Lifetime
- 2002-07-03 CN CNA028135555A patent/CN1636054A/zh active Pending
- 2002-07-03 WO PCT/US2002/020998 patent/WO2003004605A2/en active Application Filing
- 2002-07-03 CN CN200910152133.XA patent/CN101696397B/zh not_active Expired - Fee Related
- 2002-07-03 US US10/189,276 patent/US20030036194A1/en not_active Abandoned
- 2002-07-03 ES ES02756367.5T patent/ES2539105T3/es not_active Expired - Lifetime
-
2003
- 2003-12-25 IL IL159578A patent/IL159578A/en unknown
-
2005
- 2005-08-16 US US11/205,433 patent/US20050282274A1/en not_active Abandoned
- 2005-09-30 HK HK10107815.6A patent/HK1141552A1/xx not_active IP Right Cessation
- 2005-10-17 US US11/252,467 patent/US20060057720A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB0400481D0 (en) | 2004-02-11 |
| EP1412481A4 (en) | 2005-01-05 |
| WO2003004605A3 (en) | 2003-11-13 |
| EP1412481A2 (en) | 2004-04-28 |
| AU2002322379B2 (en) | 2007-02-15 |
| CA2453068C (en) | 2018-02-20 |
| US20060057720A1 (en) | 2006-03-16 |
| EP1412481B1 (en) | 2015-04-01 |
| CN1636054A (zh) | 2005-07-06 |
| GB2392674B (en) | 2005-08-10 |
| CN101696397A (zh) | 2010-04-21 |
| US20050282274A1 (en) | 2005-12-22 |
| WO2003004605A2 (en) | 2003-01-16 |
| IL159578A0 (en) | 2004-06-01 |
| IL159578A (en) | 2010-11-30 |
| HK1141552A1 (en) | 2010-11-12 |
| CN101696397B (zh) | 2015-07-08 |
| GB2392674A (en) | 2004-03-10 |
| CA2453068A1 (en) | 2003-01-16 |
| JP2004535808A (ja) | 2004-12-02 |
| US20030021771A1 (en) | 2003-01-30 |
| US20030036194A1 (en) | 2003-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2539105T3 (es) | Células mesenquimatosas y osteoblastos procedentes de células madre embrionarias humanas | |
| Leboy et al. | Dexamethasone induction of osteoblast mRNAs in rat marrow stromal cell cultures | |
| Chen et al. | Stimulation of chondrogenesis in limb bud mesoderm cells by recombinant human bone morphogenetic protein 2B (BMP-2B) and modulation by transforming growth factor β1 and β2 | |
| Bastami et al. | Induced pluripotent stem cells as a new getaway for bone tissue engineering: a systematic review | |
| Egusa et al. | Gingival fibroblasts as a promising source of induced pluripotent stem cells | |
| Betsholtz et al. | Growth factor‐induced proliferation of human fibroblasts in serum‐free culture depends on cell density and extracellular calcium concentration | |
| Vilamitjana-Amedee et al. | Human bone marrow stromal cells express an osteoblastic phenotype in culture | |
| Takeda et al. | Can the life span of human marrow stromal cells be prolonged by bmi‐1, E6, E7, and/or telomerase without affecting cardiomyogenic differentiation? | |
| Darmon et al. | Isolation of myoblastic, fibro-adipogenic, and fibroblastic clonal cell lines from a common precursor and study of their requirements for growth and differentiation | |
| JP5266297B2 (ja) | 安定な神経幹細胞系 | |
| US20100291042A1 (en) | Multipotent stem cells and uses thereof | |
| US20110306130A1 (en) | Induction of pluripotent stem cells into mesodermal lineages | |
| WO2010042800A1 (en) | Methods of reprogramming somatic cells and methods of use for such cells | |
| JP2011525798A (ja) | 歯髄類似細胞（ｄｐｍｓｃ）ならびにその単離および使用の方法 | |
| Stiles et al. | Reciprocal autocrine and paracrine regulation of growth of mesenchymal and alveolar epithelial cells from fetal lung | |
| Ning et al. | Differentiation of mouse embryonic stem cells into dental epithelial-like cells induced by ameloblasts serum-free conditioned medium | |
| Pi et al. | Differential expression of periodontal ligament‐specific markers and osteogenic differentiation in human papilloma virus 16‐immortalized human gingival fibroblasts and periodontal ligament cells | |
| Schönitzer et al. | Sox2 is a potent inhibitor of osteogenic and adipogenic differentiation in human mesenchymal stem cells | |
| CN110184299B (zh) | 诱导体细胞重编程的因子以及使用该因子诱导体细胞重编程的方法 | |
| Pérez-Campo et al. | Generation and characterization of two immortalized human osteoblastic cell lines useful for epigenetic studies | |
| Piersanti et al. | Lentiviral transduction of human postnatal skeletal (stromal, mesenchymal) stem cells: in vivo transplantation and gene silencing | |
| Lomri et al. | Genomic insertion of the SV-40 large T oncogene in normal adult human trabecular osteoblastic cells induces cell growth without loss of the differentiated phenotype | |
| US8835177B2 (en) | Method for transfer of gene into fat cell or progenitor fat cell | |
| CN101400791A (zh) | 使用nanog将星形胶质细胞去分化为神经干细胞 | |
| Truman et al. | The effect of substrate and epidermal growth factor on human placental trophoblast cells in culture |